Sign in
CompletedNo phase

Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.

Key facts

Who runs it
University Hospital, Bordeaux
Where
France2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
9 people enrolled
Started
16 Feb 2022
Ended
22 Apr 2024
Type of study
Interventional
Treatments tested
  • Piperacillin-tazobactam
Record updated
19 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patient above 18 year-old admitted to intensive care unit
  • ESBL-E fecal carriage according to current screening recommendations
  • Suspicion of ventilator-associated pneumonia according to ICU society guidelines

Who cannot take part

  • Known fecal carriage of Carbapenemase-producing Enterobacteriaceae or multi-drug resistant A. baumanii during the past 6 months
  • Treatment with piperacillin-tazobactam in the 10 previous days
  • Infection with a bacteria resistant to piperacillin-tazobactam during the past 6 months
  • Proven hypersensitivity to penicillin or tazobactam
  • Neutropenia (neutrophils count < 500/mm3)
  • Septic shock according to Sepsis-3 classification
  • Pregnancy or breastfeeding
  • Curatorship or guardianship
  • Prisoners
  • No health insurance

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Antimicrobial resistance is a major threat worldwide and now concerns last-ressource antibiotics such as carbapenems. As the resistance to carbapenems is directly due to their use, their spare has become a public health emergency. Their efficacy in ventilator-associated pneumonia has never been compared to other classes of antibiotics such as piperacillin-tazobactam which can be an alternative to carbapenems.

The group in the trial

  • InterventionTreatment being tested

    The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.

    Treatment: Piperacillin-tazobactam

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Antimicrobial Therapy for Ventilator-associated Pneumonia Among Patients Colonized With Extended-spectrum Beta-lactamase-producing Enterobacteriaceae : Efficacy of a Strategy Using Piperacillin-tazobactam as Empirical Treatment.
Record updated
19 May 2026